Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3390148 | 0.89 | CHRNA7 (0.48) | DGAT1CHRNA7PDE4BKMT2AMEN1 | |
| SCHEMBL3390921 | 0.88 | CHRNA7 (0.54) | DGAT1CHRNA7KMT2AMEN1RAB9A | |
| SCHEMBL3391064 | 0.87 | CHRNA7 (0.46) | CHRNA7PDE4BMAPTALDH1A1HPGD | |
| SCHEMBL3388395 | 0.85 | NPC1 (0.46) | CHRNA7PDE4BKMT2AMEN1NPC1 | |
| SCHEMBL3393420 | 0.82 | CHRNA7 (0.46) | CHRNA7PDE4BKMT2AMEN1NPC1 | |
| SCHEMBL3393090 | 0.81 | NPC1 (0.48) | DGAT1CHRNA7PDE4BKMT2AMEN1 | |
| SCHEMBL3388415 | 0.81 | PDE5A (0.43) | DGAT1CHRNA7PDE4BKMT2AMEN1 | |
| SCHEMBL3390544 | 0.81 | ABCB1 (0.44) | CHRNA7PDE4BNPC1RAB9AMAPT | |
| SCHEMBL3391632 | 0.81 | HPGD (0.47) | CHRNA7KMT2AMEN1NPC1RAB9A | |
| SCHEMBL3331566 | 0.81 | MMP13 (0.48) | CHRNA7KMT2AMEN1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713810-B1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH AS (DK) | 2010-12-29 | — | — | EP | claimed |
| US-20100130482-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | PETERS DAN | 2010-05-27 | — | — | US | claimed |
| US-20080227772-A1 | Diazabicyclic Aryl Derivatives as Nicotinic Acetylcholine Receptor Ligands | NEUROSEARCH A/S | 2008-09-18 | — | — | US | claimed |
| EP-1713810-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2006-10-25 | — | — | EP | claimed |
| WO-2005075482-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2005-08-18 | — | — | WO | claimed |
| EP-1713810-B1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH AS (DK) | 2010-12-29 | — | — | EP | disclosed |
| US-20100130482-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | PETERS DAN | 2010-05-27 | — | — | US | disclosed |
| US-20080227772-A1 | Diazabicyclic Aryl Derivatives as Nicotinic Acetylcholine Receptor Ligands | NEUROSEARCH A/S | 2008-09-18 | — | — | US | disclosed |
| EP-1713810-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005075482-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130482-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA6, CHRNA10, CHRNA2 | DGAT1 1693/4885CHRNA7 5/4885PDE4B 304/4885 |
| US-20080227772-A1 | Diazabicyclic Aryl Derivatives as Nicotinic Acetylcholine Receptor Ligands | CHRNA6, CHRNA10, CHRNA2 | DGAT1 1693/4885CHRNA7 5/4885PDE4B 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.